UTHR
United Therapeutics Corp
$
304.500
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
307.270
Open
306.800
VWAP
305.46
Vol
310.92K
Mkt Cap
13.73B
Low
302.1101
Amount
94.97M
EV/EBITDA(TTM)
6.84
Total Shares
44.37M
EV
10.61B
EV/OCF(TTM)
7.52
P/S(TTM)
4.91
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
803.65M
+12.41%
--
--
830.98M
+10.96%
--
--
803.69M
+9.21%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for United Therapeutics Corporation (UTHR) for FY2025, with the revenue forecasts being adjusted by 2.45% over the past three months. During the same period, the stock price has changed by 2.51%.
Revenue Estimates for FY2025
Revise Upward
+2.45%
In Past 3 Month
Stock Price
Go Up
+2.51%
In Past 3 Month
11 Analyst Rating
22.13% Upside
Wall Street analysts forecast UTHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UTHR is 371.90 USD with a low forecast of 314.00 USD and a high forecast of 432.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
3 Hold
0 Sell
Moderate Buy
22.13% Upside
Current: 304.500
Low
314.00
Averages
371.90
High
432.00
22.13% Upside
Current: 304.500
Low
314.00
Averages
371.90
High
432.00
Oppenheimer
Oppenheimer
Outperform
maintain
$510
2025-07-14
Reason
Oppenheimer
Oppenheimer
Price Target
$510
2025-07-14
maintain
Outperform
Reason
Oppenheimer says the firm's proprietary upside/downside scenario analysis of potential stock moves and Oppenheimer's implied valuation for United Therapeutics point to a favorable risk-reward ahead of TYVASO Phase 3 TETON-2 readout in IPF in September. TETON-2 is a major late-stage catalyst for the IPF space, which has seen many failures. The firm's analysis suggests that shares are currently pricing in $65/share for TYVASO/IPF, far below its estimate, likely assuming a mixed outcome. Overall, depending on the outcome, Oppenheimer sees the setup skewed to the upside with shares trading to $450/share with $235 as the floor supported by ralinepag/PAH as a near-term catalyst cushion. The firm has an Outperform rating on the shares with a price target of $510.
Morgan Stanley
Equal Weight
downgrade
$348 -> $328
2025-07-10
Reason
Morgan Stanley
Price Target
$348 -> $328
2025-07-10
downgrade
Equal Weight
Reason
Morgan Stanley lowered the firm's price target on United Therapeutics to $328 from $348 and keeps an Equal Weight rating on the shares. Year-to-date, large cap pharma and biotech companies have both underperformed given the macro environment, while multiple areas of policy uncertainty remain, including drug pricing dynamics, tariff and transfer pricing exposure, and FDA staffing changes, the analyst tells investors in a research note. The firm is modeling Tyvaso/total revenue of $442M/$768M vs. consensus expectations of $483M/$805M.
JPMorgan
Jessica Fye
Overweight
downgrade
$350 -> $330
2025-07-08
Reason
JPMorgan
Jessica Fye
Price Target
$350 -> $330
2025-07-08
downgrade
Overweight
Reason
JPMorgan analyst Jessica Fye lowered the firm's price target on United Therapeutics to $330 from $350 and keeps an Overweight rating on the shares. The firm sees the upcoming Phase III TETON 2 data for Tyvaso in idiopathic pulmonary fibrosis as a key event for the stock. The readout offers "significantly more upside than downside," the analyst tells investors in a research note.
UBS
Buy
downgrade
$410 -> $385
2025-06-30
Reason
UBS
Price Target
$410 -> $385
2025-06-30
downgrade
Buy
Reason
UBS lowered the firm's price target on United Therapeutics to $385 from $410 and keeps a Buy rating on the shares. UBS sees favorable risk/reward on the stock from current valuation heading into the idiopathic pulmonary fibrosis read-out in Q3, which may be a significant binary clinical catalyst, and expects Tyvaso to benefit from a seasonally strong Q2 and Q3, the analyst tells investors in a research note.
Cantor Fitzgerald
NULL -> Overweight
initiated
$405
2025-06-02
Reason
Cantor Fitzgerald
Price Target
$405
2025-06-02
initiated
NULL -> Overweight
Reason
Cantor Fitzgerald initiated coverage of United Therapeutics with an Overweight rating and $405 price target.
BofA
Buy
maintain
$22 -> $25
2025-05-26
Reason
BofA
Price Target
$22 -> $25
2025-05-26
maintain
Buy
Reason
BofA raised the firm's price target on Liquidia (LQDA) to $25 from $22 and keeps a Buy rating on the shares. The company's Yutrepia was approved as a 505b2 alternative to United Therapeutics' (UTHR) Tyvaso, the analyst tells investors in a research note. The firm says the Yutrepia label is highly similar Tyvaso, given the 505b2 nature of the regulatory program. BofA finds Liquidia shares undervalued relative to the peak sales opportunity.
See All Ratings
Valuation Metrics
The current forward P/E ratio for United Therapeutics Corp (UTHR.O) is 10.98, compared to its 5-year average forward P/E of 11.98. For a more detailed relative valuation and DCF analysis to assess United Therapeutics Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
11.98
Current PE
10.98
Overvalued PE
13.80
Undervalued PE
10.17
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
6.42
Current EV/EBITDA
5.28
Overvalued EV/EBITDA
7.79
Undervalued EV/EBITDA
5.05
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
4.64
Current PS
4.22
Overvalued PS
5.23
Undervalued PS
4.04
Financials
Annual
Quarterly
FY2025Q1
YoY :
+17.22%
794.40M
Total Revenue
FY2025Q1
YoY :
+7.44%
382.80M
Operating Profit
FY2025Q1
YoY :
+5.09%
322.20M
Net Income after Tax
FY2025Q1
YoY :
+7.46%
6.63
EPS - Diluted
FY2025Q1
YoY :
+14.19%
386.30M
Free Cash Flow
FY2025Q1
YoY :
-0.99%
88.36
Gross Profit Margin - %
FY2025Q1
YoY :
+25.13%
37.69
FCF Margin - %
FY2025Q1
YoY :
-10.34%
40.56
Net Margin - %
FY2025Q1
YoY :
+3.57%
19.13
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
32.5M
USD
12
3-6
Months
35.2M
USD
15
6-9
Months
86.8M
USD
25
0-12
Months
45.7M
USD
26
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
85.7K
Volume
2
6-9
Months
308.9K
Volume
5
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
46.0K
Volume
Months
6-9
3
66.8K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
32.5M
USD
12
3-6
Months
35.2M
USD
15
6-9
Months
86.8M
USD
25
0-12
Months
45.7M
USD
26
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
UTHR News & Events
Events Timeline
2025-06-24 (ET)
2025-06-24
07:02:36
United Therapeutics, Intermountain treat first patient with miroliverELAP
2025-06-23 (ET)
2025-06-23
07:15:33
United Therapeutics concludes enrollment in ADVANCE OUTCOMES study
2025-06-10 (ET)
2025-06-10
08:13:41
United Therapeutics falls after Insmed's TPIP meets endpoints in study
Sign Up For More Events
Sign Up For More Events
News
9.5
07-16NewsfilterUnited Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025
4.0
07-14NASDAQ.COMThe Implied Analyst 12-Month Target For QQQJ
4.0
07-08BenzingaJP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $330
Sign Up For More News
People Also Watch
XPO
XPO Inc
138.310
USD
+1.93%
AZPN
Aspen Technology Inc
0
USD
+0.01%
HOLX
Hologic Inc
66.500
USD
+0.61%
HEI.A
HEICO Corp
253.620
USD
+0.85%
FNF
Fidelity National Financial Inc
57.120
USD
+1.22%
BSBR
Banco Santander Brasil SA
4.760
USD
-0.42%
WES
Western Midstream Partners LP
40.760
USD
+0.27%
BAX
Baxter International Inc
29.220
USD
+1.56%
UMC
United Microelectronics Corp
7.300
USD
-0.27%
USFD
US Foods Holding Corp
82.260
USD
+0.54%
FAQ
What is United Therapeutics Corp (UTHR) stock price today?
The current price of UTHR is 304.5 USD — it has decreased -0.62 % in the last trading day.
What is United Therapeutics Corp (UTHR)'s business?
What is the price predicton of UTHR Stock?
What is United Therapeutics Corp (UTHR)'s revenue for the last quarter?
What is United Therapeutics Corp (UTHR)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for United Therapeutics Corp (UTHR)'s fundamentals?
How many employees does United Therapeutics Corp (UTHR). have?